Eli Lilly and Company (LLY)
Overview
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Explore More Data
Key Information
Stock Snapshot (Updated: Nov 05 04:00 PM EST)
Capital Structure (Updated: Nov 05 04:00 PM EST)
Calendar Events (Upcoming Earnings & Revenue Forecasts)
| Earnings | |
| Earnings Date | 2025-10-30 |
| Earnings Call | 2025-10-30 |
| Avg EPS Estimate | 7.0776 |
| Low EPS Estimate | 6.3997 |
| High EPS Estimate | 8.78 |
| Revenue | |
| Avg Revenue Forecast | 17,598,144,230 |
| Low Revenue Forecast | 17,274,000,000 |
| High Revenue Forecast | 17,897,255,120 |
LLY Liquidity Indicators Shows key metrics that reflect cash availability and short-term payment ability
| Field | Value | Description |
|---|---|---|
| Cash Holdings | $9,913,499,648 | Cash on hand, which directly shows a company's ability to meet short-term obligations. |
| Quick Ratio | 0.724 | The quick ratio, which excludes inventory, measures short-term solvency; a value above 1 is considered relatively safe. |
| Current Ratio | 1.546 | The current ratio, calculated as current assets divided by current liabilities; the higher the value, the better the liquidity. |
| Total Debt | $42,577,600,512 | Total liabilities, used together with cash and liquidity ratios to assess debt burden. |
LLY Profitability Indicators Shows key metrics that reflect overall earnings, margins, and core business profitability
| Field | Value | Description |
|---|---|---|
| EBITDA | $28,728,600,576 | EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization), which measures the profitability of core operations. |
| Operating Cash Flow | $16,062,199,808 | Operating cash flow, which reflects a company's cash-generating ability. |
| Free Cash Flow | $1,397,924,992 | Free cash flow, after deducting capital expenditures, which can be used for dividends or reinvestment. |
| Gross Margin | 83.03% | Gross margin; a higher value indicates stronger product profitability. |
| Operating Margin | 48.29% | Operating margin; slightly negative, indicating high operating costs. |
| Profit Margin | 30.99% | Net profit margin, which reflects overall profitability. |
LLY Leverage & Financial Health Indicators Shows key metrics that reflect debt levels, liquidity, and overall financial stability
| Field | Value | Description |
|---|---|---|
| Debt/Equity Ratio | 178.52% | Low leverage level, indicating the company has low debt pressure. |
| Total Debt | $42,577,600,512 | Used together with cash and EBITDA to assess debt-paying ability. |
LLY Growth Indicators Shows key financial metrics that reflect profitability, cash flow, and business expansion
| Field | Value | Description |
|---|---|---|
| Revenue Growth (YoY) | 53.90% | Rapid revenue growth, indicating fast business expansion. |
| Earnings Growth (YoY) | 480.40% | Significant EPS growth, indicating rapid improvement in profitability. |
Financial Data for LLY (Key ratios, margins, and cash flow)
| Field | Value | Description |
|---|---|---|
| Current Price | $925.81 | Latest stock trading price |
| Price Target (High) | $1190 | Analyst highest expected price |
| Price Target (Low) | $700 | Analyst lowest expected price |
| Price Target (Average) | $921.19 | Average target price across analysts |
| Price Target (Median) | $948 | Median of target prices |
| Average Rating Score | 1.76 | Average analyst rating (1=Strong Buy, 5=Sell) |
| Consensus Recommendation | buy | Consensus rating |
| Analyst Coverage Count | 27 | Number of analysts providing estimates |
| Cash Holdings | $9,913,499,648 | Total cash held by the company |
| Cash per Share | $11.07 | Cash value per outstanding share |
| Total Debt | $42,577,600,512 | Company's total debt |
| Quick Ratio | 0.724 | Ability to cover short-term liabilities (excludes inventory) |
| Current Ratio | 1.546 | Overall short-term liquidity |
| Debt/Equity Ratio | 178.52% | Leverage ratio: Debt / Equity |
| EBITDA | $28,728,600,576 | Earnings before interest, taxes, depreciation & amortization |
| Total Revenue | $59,419,799,552 | Total company revenue |
| Revenue per Share | $66.148 | Total revenue divided by shares outstanding |
| Gross Profit | 83.03% | Revenue minus cost of goods sold |
| Return on Assets | 17.60% | Net income / Total assets |
| Return on Equity | 96.47% | Net income / Shareholder equity |
| Earnings Growth (YoY) | 480.40% | Year-over-year EPS growth |
| Revenue Growth (YoY) | 53.90% | Year-over-year revenue growth |
| Gross Margin | 83.03% | Gross profit / Total revenue |
| EBITDA Margin | 48.35% | EBITDA / Revenue |
| Operating Margin | 48.29% | Operating income / Revenue |
| Profit Margin | 30.99% | Net income / Revenue |
| Free Cash Flow | $1,397,924,992 | Cash left after capital expenditures |
| Operating Cash Flow | $16,062,199,808 | Cash from core business operations |
| Currency | USD | Reported in US dollars |
| Last Updated | 2025-11-05 | Data source from Yahoo |